SMARCA2 and adenocarcinoma: Positive nuclear staining of SMARCA2 and concomitant nuclear staining of SMARCA2 and SMARCA4 were both associated with better five-year survival in 300 NSCLC cases (150 adenocarcinoma and 150 SCC).